NCT Number: NCT00216892
Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris
Patients with psoriasis vulgaris of the trunk and/or limbs are randomised to treatment with:
1. 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8 weeks of calcipotriol cream 2. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of calcipotriol cream on weekdays/ (calcipotriol plus betamethasone dipropionate) ointment on weekends 3. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of vehicle of calcipotriol cream
The objective is to compare the efficacy and safety of the different treatment regimens
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Universitair Ziekenhuis, Ghent, Belgium
About this study
A phase IV study of different treatment regimens of calcipotriol 50 mcg/g cream and combination (calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) ointment following treatment with combination ointment in psoriasis vulgaris
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients with psoriasis vulgaris of trunk and/or limbs
Exclusion criteria
-
Treatment and study plan
Primary outcomes
-
Efficacy of regimen (a) versus regimen (c) by % change in PASI at week 12
Secondary outcomes
-
Efficacy of regimen (b) versus regimen (c) at week 12, safety of regimen (a) versus (c), safety of regimen (b) versus (c)
Sponsors and collaborators
Lead sponsor
LEO Pharma
Industry
Registry information
Official study title
Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris
Important dates
- Study start
- 2005
- Study completion
- 2005
- First posted
- Sep 22, 2005
- Registry last updated
- Feb 24, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
NCT04306315
Psoriasis Vulgaris
Brussels, Belgium
View Trial DetailsEfficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)
NCT03372811
Psoriasis, Psoriasis Vulgaris
New York, United States
View Trial DetailsDose Reduction of IL17 and IL23 Inhibitors in Psoriasis
NCT04340076
Psoriasis, Psoriasis Vulgaris
Brussels, Belgium
View Trial DetailsTopical SGX302 for Mild-to-Moderate Psoriasis
NCT05442190
Plaque Psoriasis, Psoriasis
San Diego, California, United States
View Trial Details